Treatments

*April 2024* Although the use of the tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) is the preferred frontline approach in patients with non-small cell lung cancer (NSCLC) with classic EGFR mutations, acquired resistance mechanisms invariably develop. “When we think about acquired resistance to TKIs, this is not limited to EGFR and ALK—it is a universal persistent…

*April 2024* Video: Dr. Joseph Treat from  Fox Chase Cancer Center discusses the LP-300 clinical trial regarding EGFR+ NSCLC in  the never smoker population. Watch video here.

*March 2024* In this podcast, Dr. Paul Wheatley-Price sits down with Dr. Amir Safavi, final-year Radiation Oncology Resident at the University of Toronto, and Dr. Jillian Tsai, Staff Radiation Oncologist at Princess Margaret Cancer Centre. They preface the chat with radiation 101, describe what "oligo-" means in the context of…

*March 2024* The phase 3 MARIPOSA trial (NCT04487080) evaluating a regimen of amivantamab-vmjw (Rybrevant) and lazertinib vs standard-of-care osimertinib (Tagrisso) for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. The combination demonstrated a longer progression-free survival (PFS) and duration…

*March 2024* Note to reader: Although Tagrisso is the preferred first-line treatment, some patients who took a 1st or 2nd generation drug as first-line (Tarceva, Afatinab) and then Tagrisso as second-line experienced a much longer PFS (progression-free survival) than those who started with Tagrisso. ABSTRACT Here, I suggest that while…

*March 2024* Abstract Introduction Characteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. Methods Clinical characteristics and outcomes were abstracted from the electronic…

*January 2024* Abstract Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-related lung cancers continue to account for the majority of diagnoses, smoking rates have been decreasing for several decades. Lung cancer in individuals who have never smoked (LCINS) is estimated to be the fifth most…

*March 2024* The publishing of data from the FLAURA21 and MARIPOSA2 trials in the fall of 2023 spurred much discussion and debate about the use of first-line chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR mutations. To clarify the role of first-line chemotherapy in this population, Suresh S. Ramalingam, MD,…

*March 2024* Stephen V. Liu, MD, Director of Thoracic Oncology and Head of Developmental Therapeutics, Georgetown University, gave an overview of the topics discussed during February’s IASLC Targeted Therapies Meeting. Isabel Preeshagul, DO, MBS, moderated the discussion. Watch it here.